You can buy or sell NLNK and other stocks, options, ETFs, and crypto commission-free!
NewLink Genetics Corporation Common Stock, also called NewLink Genetics, is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Read More The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
52 Week High
52 Week Low
Markets InsiderMay 6
NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
AMES, Iowa, May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences: Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas Management will present on Thursday, May 16 at 8:40 AM PT / 11:40 AM ET Immuno-Oncology 2019 World Congress on May 23-24 in Barcelona, Spain Poster presentation of Abstract #188 entitled, “A Phase 1 Clinical Trial of NLG802, a...
Yahoo FinanceApr 26
NewLink Genetics Corporation (NASDAQ:NLNK): Earnings Expected To Remain Subdued
NewLink Genetics Corporation's (NASDAQ:NLNK) released its most recent earnings update in December 2018, which indicated that losses became smaller relative to the prior year's level - great news for investors Below, I've presented key growth figures on how market analysts perceive NewLink Genetics's earnings growth outlook over the next few years and whether the future looks brighter.
Expected Jul 30, After Hours